See today's BioWorld
To read the full article sign up for free or sign in.

Indukine potential unmasked with early Werewolf data

Nov. 3, 2023
By Randy Osborne
Shares of Werewolf Therapeutics Inc. (NASDAQ:HOWL) reflected enthusiasm on Wall Street for the prospect, albeit early stage, of systemically delivering a masked native interleukin-2 (IL-2) cytokine to cancer patients.
BioWorld Clinical Conferences Society for Immunotherapy of Cancer Cancer Immuno-oncology